Electrophysiological evaluation of visual pathways in paclitaxel-treated patients

V. Scaioli; A. Caraceni; C. Martini; S. Curzi; G. Capri; G. Luca

doi:10.1007/s11060-005-9008-x

Electrophysiological evaluation of visual pathways in paclitaxel-treated patients

V. Scaioli, A. Caraceni, C. Martini, S. Curzi, G. Capri, G. Luca

Research output: Contribution to journal › Article

Abstract

As paclitaxel may induce positive spontaneous visual symptoms or persistent visual loss, we carried out this electrophysiological study in an attempt to clarify the underlying pathophysiological mechanisms of visual pathway involvement. The study involved 30 breast cancer patients: 14 were treated with paclitaxel alone (group A) and 16 with paclitaxel and adriamycin (group B). Pattern visual evoked potentials (VEPs), and transient, 30 Hz flicker (FLK) and oscillatory potential (OP) white flash electroretinograms (ERGs), were recorded before treatment, after the third and sixth therapeutic cycle, and at the end of the programmed regimen. Pretreatment: Abnormal VEP and OP and FLK changes occurred more than 75% of patients; transient ERGs were normal in more than 90%. Serial recordings: VEPs remained unchanged in both goups. In group A, ERG b-wave latency significantly increased (ANOVA P

Original language	English
Pages (from-to)	79-87
Number of pages	9
Journal	Journal of Neuro-Oncology
Volume	77
Issue number	1
DOIs	https://doi.org/10.1007/s11060-005-9008-x
Publication status	Published - Mar 2006

Keywords

Chemotherapy
Electroretinogram
Ocular toxicity
Paclitaxel
Tamoxifen
Visual evoked potentials

ASJC Scopus subject areas

Clinical Neurology
Cancer Research
Oncology
Neuroscience(all)

Access to Document

10.1007/s11060-005-9008-x

Fingerprint Dive into the research topics of 'Electrophysiological evaluation of visual pathways in paclitaxel-treated patients'. Together they form a unique fingerprint.

Cite this

Scaioli, V., Caraceni, A., Martini, C., Curzi, S., Capri, G., & Luca, G. (2006). Electrophysiological evaluation of visual pathways in paclitaxel-treated patients. Journal of Neuro-Oncology, 77(1), 79-87. https://doi.org/10.1007/s11060-005-9008-x

@article{e98b18d0a5364efa9a43e40a47695e61,

title = "Electrophysiological evaluation of visual pathways in paclitaxel-treated patients",

abstract = "As paclitaxel may induce positive spontaneous visual symptoms or persistent visual loss, we carried out this electrophysiological study in an attempt to clarify the underlying pathophysiological mechanisms of visual pathway involvement. The study involved 30 breast cancer patients: 14 were treated with paclitaxel alone (group A) and 16 with paclitaxel and adriamycin (group B). Pattern visual evoked potentials (VEPs), and transient, 30 Hz flicker (FLK) and oscillatory potential (OP) white flash electroretinograms (ERGs), were recorded before treatment, after the third and sixth therapeutic cycle, and at the end of the programmed regimen. Pretreatment: Abnormal VEP and OP and FLK changes occurred more than 75% of patients; transient ERGs were normal in more than 90%. Serial recordings: VEPs remained unchanged in both goups. In group A, ERG b-wave latency significantly increased (ANOVA P ",

keywords = "Chemotherapy, Electroretinogram, Ocular toxicity, Paclitaxel, Tamoxifen, Visual evoked potentials",

author = "V. Scaioli and A. Caraceni and C. Martini and S. Curzi and G. Capri and G. Luca",

year = "2006",

month = mar,

doi = "10.1007/s11060-005-9008-x",

language = "English",

volume = "77",

pages = "79--87",

journal = "Journal of Neuro-Oncology",

issn = "0167-594X",

publisher = "Springer New York LLC",

number = "1",

}

TY - JOUR

T1 - Electrophysiological evaluation of visual pathways in paclitaxel-treated patients

AU - Scaioli, V.

AU - Caraceni, A.

AU - Martini, C.

AU - Curzi, S.

AU - Capri, G.

AU - Luca, G.

PY - 2006/3

Y1 - 2006/3

N2 - As paclitaxel may induce positive spontaneous visual symptoms or persistent visual loss, we carried out this electrophysiological study in an attempt to clarify the underlying pathophysiological mechanisms of visual pathway involvement. The study involved 30 breast cancer patients: 14 were treated with paclitaxel alone (group A) and 16 with paclitaxel and adriamycin (group B). Pattern visual evoked potentials (VEPs), and transient, 30 Hz flicker (FLK) and oscillatory potential (OP) white flash electroretinograms (ERGs), were recorded before treatment, after the third and sixth therapeutic cycle, and at the end of the programmed regimen. Pretreatment: Abnormal VEP and OP and FLK changes occurred more than 75% of patients; transient ERGs were normal in more than 90%. Serial recordings: VEPs remained unchanged in both goups. In group A, ERG b-wave latency significantly increased (ANOVA P

AB - As paclitaxel may induce positive spontaneous visual symptoms or persistent visual loss, we carried out this electrophysiological study in an attempt to clarify the underlying pathophysiological mechanisms of visual pathway involvement. The study involved 30 breast cancer patients: 14 were treated with paclitaxel alone (group A) and 16 with paclitaxel and adriamycin (group B). Pattern visual evoked potentials (VEPs), and transient, 30 Hz flicker (FLK) and oscillatory potential (OP) white flash electroretinograms (ERGs), were recorded before treatment, after the third and sixth therapeutic cycle, and at the end of the programmed regimen. Pretreatment: Abnormal VEP and OP and FLK changes occurred more than 75% of patients; transient ERGs were normal in more than 90%. Serial recordings: VEPs remained unchanged in both goups. In group A, ERG b-wave latency significantly increased (ANOVA P

KW - Chemotherapy

KW - Electroretinogram

KW - Ocular toxicity

KW - Paclitaxel

KW - Tamoxifen

KW - Visual evoked potentials

UR - http://www.scopus.com/inward/record.url?scp=33745056075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745056075&partnerID=8YFLogxK

U2 - 10.1007/s11060-005-9008-x

DO - 10.1007/s11060-005-9008-x

M3 - Article

C2 - 16132528

AN - SCOPUS:33745056075

VL - 77

SP - 79

EP - 87

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 1

ER -